Big Pharma will survive “unscathed” from this year’s patent cliff, says report
Most global pharmaceutical firms will survive this year’s patent cliff unscathed, according to a report from Standard &, Poor’s.
The report entitled ‘Why Global Pharmaceutical Firms Won’t Fall Off A Patent Cliff’ claimed that whilst most big pharmaceutical companies won’t thrive in the current environment, they would survive.
“We believe a mix of factors will keep the sector resilient to patent expiries. Their pipeline of new molecular entities in late-stage development suggests they can match lost sales from patent expiries with future sales growth if these projects gain regulatory approval.
“Furthermore, companies are finding growth in high-potential markets such as oncology and diabetes treatments, and in fast-growing emerging markets.”
Olaf Toelke, S&,P’s credit analyst
Big companies are also buying up smaller medical firms, which is diversifying their product ranges, to protect themselves from significant losses.
TEXT-S&,P report: Big Pharma won’t fall off a patent cliff (Yahoo finance)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.